NYSE:CBM - Cambrex Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$56.05 +0.35 (+0.63 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$55.70
Today's Range$55.75 - $56.55
52-Week Range$42.55 - $62.30
Volume206,600 shs
Average Volume330,571 shs
Market Capitalization$1.86 billion
P/E Ratio17.68
Dividend YieldN/A
Beta2.27
Cambrex logoCambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals. The company serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics. The company sells its products directly, as well as through independent agents. Cambrex Corporation was founded in 1981 and is headquartered in East Rutherford, New Jersey.

Receive CBM News and Ratings via Email

Sign-up to receive the latest news and ratings for CBM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNYSE:CBM
CUSIP13201110
Phone201-804-3000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.04
Quick Ratio3.90

Price-To-Earnings

Trailing P/E Ratio17.68
Forward P/E Ratio20.53
P/E Growth1.38

Sales & Book Value

Annual Sales$534.46 million
Price / Sales3.46
Cash Flow$4.1922 per share
Price / Cash13.37
Book Value$16.62 per share
Price / Book3.37

Profitability

EPS (Most Recent Fiscal Year)$3.17
Net Income$102.45 million
Net Margins18.69%
Return on Equity21.00%
Return on Assets15.20%

Miscellaneous

Employees1,228
Outstanding Shares32,960,000
Market Cap$1,857.27

Cambrex (NYSE:CBM) Frequently Asked Questions

What is Cambrex's stock symbol?

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

How were Cambrex's earnings last quarter?

Cambrex Co. (NYSE:CBM) released its earnings results on Thursday, May, 3rd. The biotechnology company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.22. The biotechnology company had revenue of $141.10 million for the quarter, compared to analyst estimates of $104.44 million. Cambrex had a return on equity of 21.00% and a net margin of 18.69%. The company's quarterly revenue was up 34.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.68 earnings per share. View Cambrex's Earnings History.

When is Cambrex's next earnings date?

Cambrex is scheduled to release their next quarterly earnings announcement on Friday, August, 3rd 2018. View Earnings Estimates for Cambrex.

What guidance has Cambrex issued on next quarter's earnings?

Cambrex issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided earnings per share (EPS) guidance of $2.80 to $3.03 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.90.

What price target have analysts set for CBM?

3 Wall Street analysts have issued 1-year price targets for Cambrex's shares. Their forecasts range from $60.00 to $60.00. On average, they anticipate Cambrex's share price to reach $60.00 in the next twelve months. This suggests a possible upside of 7.0% from the stock's current price. View Analyst Ratings for Cambrex.

What is the consensus analysts' recommendation for Cambrex?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Cambrex's key competitors?

Who are Cambrex's key executives?

Cambrex's management team includes the folowing people:
  • Mr. Steven M. Klosk, Pres, CEO & Director (Age 61)
  • Mr. Tom G. Vadaketh, Exec. VP & CFO (Age 55)
  • Mr. Shawn P. Cavanagh, Exec. VP & COO (Age 52)
  • Ms. Samantha M. Hanley, VP, Gen. Counsel & Corp. Sec. (Age 40)
  • Mr. Gregory P. Sargen, Exec. VP of Corp. Devel. & Strategy (Age 52)

Has Cambrex been receiving favorable news coverage?

Media coverage about CBM stock has trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cambrex earned a news impact score of 0.15 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 46.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Cambrex's major shareholders?

Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include American Capital Management Inc. (2.19%), Summit Creek Advisors LLC (0.47%), Peregrine Capital Management LLC (0.41%), Cambiar Investors LLC (0.31%), Confluence Investment Management LLC (0.28%) and Scout Investments Inc. (0.27%). Company insiders that own Cambrex stock include Gregory Sargen, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh and Steven M Klosk. View Institutional Ownership Trends for Cambrex.

Which major investors are selling Cambrex stock?

CBM stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Municipal Employees Retirement System of Michigan and Scout Investments Inc.. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

Which major investors are buying Cambrex stock?

CBM stock was acquired by a variety of institutional investors in the last quarter, including Cambiar Investors LLC, American Capital Management Inc., Summit Creek Advisors LLC, Bank of Montreal Can and Confluence Investment Management LLC. View Insider Buying and Selling for Cambrex.

How do I buy shares of Cambrex?

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cambrex's stock price today?

One share of CBM stock can currently be purchased for approximately $56.05.

How big of a company is Cambrex?

Cambrex has a market capitalization of $1.86 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.

How can I contact Cambrex?

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]


MarketBeat Community Rating for Cambrex (NYSE CBM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  160 (Vote Underperform)
Total Votes:  335
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Featured Article: Relative Strength Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.